Boosting Investment in R&I: €100,000 donation by kENUP Foundation to Malta’s COVID-19 R&D Fund
1.8.2020 11:23:00 EEST | Business Wire | Press release
kENUP Foundation has presented €100,000 donation into Malta’s COVID-19 R&D Fund. The Fund is managed jointly by the Malta Council for Science and Technology (MCST) and Malta Enterprise with the support of the Ministry for Finance and Financial Services, and the Ministry for the Economy, Investment & Small Businesses. The Malta fund will see €5.3M funnelled into developing innovative and improved scientific and technological approaches to the challenges raised by COVID-19 and future pandemics.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200801005005/en/
Boosting Investment in R&I: €100,000 donation by kENUP Foundation to Malta’s COVID-19 R&D Fund (Photo: Business Wire)
kENUP, a Malta-based not-for-profit global partnership in innovation, promotes research-based innovation for Europe with public and societal benefit. Holm Keller, Chairman of kENUP Foundation said, “We are very grateful to the Maltese Government for the initial support in the setting up of the Foundation in the Republic of Malta. kENUP Foundation is supporting the provision of financing for companies engaged in the development of innovative products aimed at fighting COVID-19. We are therefore very happy to also contribute to the Maltese COVID-19 R&D Fund and to support projects designed to protect the Maltese people and beyond."
“With this significant donation, kENUP is giving the Malta Council for Science and Technology its appreciated support by boosting the Euro 5.3 Million COVID-19 R&D Fund set up using central government funding earlier this year,” said Dr Jeffrey Pullicino Orlando, Executive Chairman of the Malta Council for Science and Technology.
In his keynote speech, Parliamentary Secretary for Financial Services and Digital Economy Hon. Clayton Bartolo said that Malta is not a newcomer to kENUP initiatives. “I know that years ago, MCST envisioned that kENUP could truly bring something new and big to Malta’s ailing research and innovation sector. Along the years, kENUP has also found this government’s help in addressing legal issues allowing for a novel concept in online tertiary education which ultimatley led to this setting up of EDU, also in Malta.”
The Parliamentary Secretary also highlighted that six years from its inception, kENUP has solidly established itself globally in innovation support particularly in the health sector. “Through this donation our country will strengthen its cause for more investment in Research & Development,” remarked Hon. Bartolo.
The video of the event can be found at https://www.covidx.eu/news/#Malta
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200801005005/en/
Contact information
Press contacts:
kENUP covidX Programme: Nadine Castillo tel: +356 99452436
MCST COVID-19 R&D fund: Giselle Calleja tel: +356 2360 2173
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Baszucki Group Funds Oxford University Clinical Trial of Ketogenic Therapy for Early Psychosis21.5.2026 14:00:00 EEST | Press release
Baszucki Group today announced a £1.17 million grant to support a randomized controlled trial at the University of Oxford assessing the feasibility, safety, and efficacy of a ketogenic diet for patients at clinical high risk of psychosis (CHR-P). Researchers will test this nutritional therapy's ability to improve patients' mental and physical health. This project builds on a growing body of research suggesting the potential of metabolic therapies in treating serious mental illness. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521877110/en/ Baszucki Group Funds £1.17 Million for University of Oxford Trial of Ketogenic Therapy for Early Psychosis Psychotic disorders carry a massive personal burden and are associated with a lower life expectancy. Psychosis does not develop immediately, but typically emerges following a period of early, subtle symptoms. Individuals in this stage, classified as CHR-P, represent a critical pr
SINOVAC Announces Extension of Deadline to Submit Payment Instructions for Previously Declared Special Cash Dividend21.5.2026 13:30:00 EEST | Press release
Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it has extended the deadline for shareholders and nominee brokers to submit payment instructions relating to the Company’s previously declared special cash dividend. The Company previously announced a special cash dividend of US$55.00 per common share, payable to valid holders of the Company’s common shares as of the close of business on May 23, 2025 ET. The Company previously informed shareholders that completed instruction materials were to be submitted prior to December 31, 2025 in order to facilitate receipt of the dividend. The Company has now extended that submission deadline to June 30, 2026. Shareholders and nominee brokers that have not yet submitted their instruction materials are reminded to do so on or before June 30, 2026 in order to facilitate payment of the dividend. If you have any questions regarding the process you need to un
Cranium AI and ISTARI Forge Global Alliance to Drive Enterprise AI Security and Governance21.5.2026 13:00:00 EEST | Press release
Cranium AI, the leading end-to-end AI Security and Governance platform, and ISTARI, a leading cyber resilience advisory firm, today announced a strategic partnership to provide global organizations with an end-to-end AI security & governance solution. As organizations accelerate AI adoption, they face a critical challenge: implementing actionable, operational AI governance while keeping pace with the speed of the AI landscape. This collaboration bridges that gap by merging Cranium’s cutting-edge AI security and governance platform with ISTARI’s deep advisory expertise in cyber risk and operating model design. Together, the firms provide a powerful, end-to-end solution for enterprises navigating the complexities of AI transformation. A Unified Vision for Sustainable AI Governance The partnership is built on a shared mission to move organizations beyond fragmented AI initiatives toward fully operationalized, secure, and governed programs. By combining Cranium’s platform automation with I
Cognite and ABB Collaborate to Integrate Agentic AI into Industrial Applications to Deliver Faster Workflows21.5.2026 13:00:00 EEST | Press release
Cognite, the leader in Industrial AI, today announced a collaboration with ABB to assess how advanced industrial AI and data capabilities can be integrated to solve key use cases in the energy sector. By adding an agentic layer to established industrial applications, including ABB Ability™ SafetyInsight™ and ABB Ability™ AlarmInsight™, using the Cognite Industrial AI and Data platform, the collaboration aims to enable "agent-to-agent" orchestration. Leading energy producer Aker BP has signed on as the first customer to implement this new generation of intelligent offerings as part of its strategy to further increase its current production efficiency of 96% and achieve a production growth target of 525,000 barrels of oil equivalent per day by 2028. Transforming Data into Actionable Business Value By breaking down traditional data silos and shifting to outcome-based software orchestration, the collaboration aims to deliver significant business value to ABB and Cognite customers, includin
BeOne Medicines Sets the Pace in Oncology at ASCO and EHA 2026 with 60+ Abstracts21.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that more than 60 abstracts across hematologic malignancies and solid tumors have been accepted for presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (May 29–June 2, Chicago) and the 2026 European Hematology Association (EHA) Congress (June 11–14, Stockholm). Continuing to raise the bar in CLL At ASCO and EHA 2026, BeOne will showcase its hematology leadership with data spanning foundational therapies and next-generation innovation across CLL, mantle cell lymphoma and other B-cell malignancies. The data emphasize impressive long-term outcomes, durability across patient populations, and a disciplined approach to advancing future regimens. Collectively, these data underscore BeOne’s strategy to lead in hematology science and patient impact by setting the standard today – while helping to shape the future of CLL. Amit Agarwal, M.D., Ph.D., Chief Medic
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom